Pharmacoeconomics of Available Treatment Options for Metastatic Prostate Cancer

被引：0
|
作者：
Steven B. Zeliadt
David F. Penson
机构：
[1] Fred Hutchinson Cancer Research Center,Division of Public Health Sciences
[2] Keck School of Medicine,Departments of Urology and Preventive Medicine
[3] University of Southern California,undefined
[4] Departments of Urology,undefined
来源：
PharmacoEconomics | 2007年 / 25卷
关键词：
Prostate Cancer; Androgen Deprivation Therapy; Flutamide; Advanced Prostate Cancer; Goserelin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The resources devoted to managing metastatic prostate cancer are enormous, yet little attention has been given to directly measuring the economic consequences of treatment alternatives. The purpose of this article was to evaluate the pharmacoeconomics of available treatments for metastatic prostate cancer, including hormone-sensitive disease, androgen-independent prostate cancer and locally advanced/progressive disease. We identified 58 articles addressing economic issues related to metastatic prostate cancer.
引用
收藏
页码：309 / 327
页数：18
相关论文
共 50 条
  • [21] Eliciting patient preferences for hormonal therapy options in the treatment of metastatic prostate cancer
    Lloyd, A.
    Penson, D.
    Dewilde, S.
    Kleinman, L.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2008, 11 (02) : 153 - 159
  • [22] Understanding how prostate cancer patients value the current treatment options for metastatic castration resistant prostate cancer
    Benidir, Tarik
    Hersey, Karen
    Finelli, Antonio
    Hamilton, Rob
    Joshua, Anthony M.
    Kulkarni, Girish
    Zlotta, Alexandre
    Fleshner, Neil
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2018, 36 (05) : 240.e13 - 240.e20
  • [23] Currently available treatment options for metastatic renal cell carcinoma
    Alekseev, B. Ya
    Kaprin, A. D.
    Kolesnikov, G. P.
    Mukhomed'yarova, A. A.
    Konopleva, F. L.
    Kalpinskiy, A. S.
    ONKOUROLOGIYA, 2018, 14 (03): : 25 - 36
  • [24] Treatment options for metastatic cervical cancer
    Jaeger, Anna
    Sachs, Charlotte
    Mueller, Volkmar
    Schmalfeldt, Barbara
    Woelber, Linn
    GYNAKOLOGIE, 2024, 57 (11): : 759 - 769
  • [25] Treatment options for metastatic colorectal cancer
    Senellart, H.
    Hiret, S.
    Bennouna, J.
    ONCOLOGIE, 2010, 12 (10) : 593 - 600
  • [26] Treating Primary Node-Positive Prostate Cancer: A Scoping Review of Available Treatment Options
    Zuur, Lotte G.
    de Barros, Hilda A.
    van der Mijn, Koen J. C.
    Vis, Andre N.
    Bergman, Andries M.
    Pos, Floris J.
    van Moorselaar, Jeroen A.
    van der Poel, Henk G.
    Vogel, Wouter V.
    van Leeuwen, Pim J.
    CANCERS, 2023, 15 (11)
  • [27] Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options
    Gartrell, Benjamin A.
    Coleman, Robert
    Efstathiou, Eleni
    Fizazi, Karim
    Logothetis, Christopher J.
    Smith, Matthew R.
    Sonpavde, Guru
    Sartor, Oliver
    Saad, Fred
    EUROPEAN UROLOGY, 2015, 68 (05) : 850 - 858
  • [28] Metastatic Prostate Cancer-A Review of Current Treatment Options and Promising New Approaches
    Posdzich, Philip
    Darr, Christopher
    Hilser, Thomas
    Wahl, Milan
    Herrmann, Ken
    Hadaschik, Boris
    Gruenwald, Viktor
    CANCERS, 2023, 15 (02)
  • [29] Cost of illness of metastatic prostate cancer: a perspective of costs for new treatment options in The Netherlands
    ter Heine, Rob
    Frederix, Geert W. J.
    Geenen, Joost W.
    Hovels, Anke M.
    van Vulpen, Marco
    Kooistra, Anko
    De Klerk, John M. H.
    Bloemendal, Haiko J.
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2017, 6 (07) : 575 - 581
  • [30] TREATMENT OF METASTATIC CANCER OF THE PROSTATE
    FOURNIER, G
    MANGIN, P
    PRESSE MEDICALE, 1995, 24 (32): : 1465 - &
12345